shutterstock_1824967073_rafapress

14 December 2023Big PharmaLiz Hockley

Acadia defends Parkinson’s drug patent against obviousness-type double patenting attack

Court rules that patent must be later-filed to be available as OTDP reference | MSN had submitted ANDA for generic version of Parkinson’s treatment Nuplazid.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Fed Circuit refuses to revive Parkinson’s disease patent

13 April 2023 Precedential decision upholds lower court’s earlier finding | Patent at heart of the dispute covers treatment patch for Parkinson’s.

LSIPR 50 2018: A decade in the making, a Parkinson’s breakthrough

6 July 2018 A team at the University of Dundee has announced a major breakthrough in the understanding of Parkinson’s disease. LSIPR heard more from Miratul Muqit and Daan van Aalten of the university’s school of life sciences.

More on this story

Fed Circuit refuses to revive Parkinson’s disease patent

13 April 2023 Precedential decision upholds lower court’s earlier finding | Patent at heart of the dispute covers treatment patch for Parkinson’s.

LSIPR 50 2018: A decade in the making, a Parkinson’s breakthrough

6 July 2018 A team at the University of Dundee has announced a major breakthrough in the understanding of Parkinson’s disease. LSIPR heard more from Miratul Muqit and Daan van Aalten of the university’s school of life sciences.

More on this story

Fed Circuit refuses to revive Parkinson’s disease patent

13 April 2023 Precedential decision upholds lower court’s earlier finding | Patent at heart of the dispute covers treatment patch for Parkinson’s.

LSIPR 50 2018: A decade in the making, a Parkinson’s breakthrough

6 July 2018 A team at the University of Dundee has announced a major breakthrough in the understanding of Parkinson’s disease. LSIPR heard more from Miratul Muqit and Daan van Aalten of the university’s school of life sciences.

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages